Comparative Pharmacology
Head-to-head clinical analysis: DUTOPROL versus SERPASIL ESIDRIX 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUTOPROL versus SERPASIL ESIDRIX 1.
DUTOPROL vs SERPASIL-ESIDRIX #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of metoprolol tartrate (beta-1-selective adrenergic receptor blocker) and hydrochlorothiazide (thiazide diuretic inhibiting Na+/Cl- cotransporter in distal convoluted tubule).
Reserpine depletes catecholamines (norepinephrine, dopamine) from central and peripheral nerve endings by irreversibly inhibiting the vesicular monoamine transporter (VMAT2), leading to reduced sympathetic outflow and vasodilation. Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
1 tablet (containing 12.5 mg hydrochlorothiazide and 50 mg losartan) orally once daily; may increase to 1 tablet (12.5 mg/100 mg) once daily if inadequate response.
1 tablet orally twice daily, titrate to response. Each tablet contains reserpine 0.1 mg and hydrochlorothiazide 25 mg.
None Documented
None Documented
Bisoprolol: 10-12 hours, allowing once-daily dosing; Hydrochlorothiazide: 6-15 hours, prolonged in renal impairment.
Reserpine: 50-100 hours (terminal); clinical effects persist due to irreversible adrenergic neuron blockade. Hydrochlorothiazide: 6-15 hours (terminal).
Renal: 40-50% as unchanged drug and metabolites (hydrochlorothiazide and bisoprolol); Fecal/Biliary: <15%.
Reserpine: renal (30% as metabolites, <1% unchanged), fecal (60% as metabolites). Hydrochlorothiazide: renal (>95% unchanged).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination